EGFR
17 drugs Oncology
5
approved indications
17
Approved Drugs
14
Companies
19
Indications
1
Therapeutic Areas
Top Drugs
Unlock Full Target Intelligence PRO
✓ Competitive landscape by company (14 companies)
✓ All 17 approved drugs
✓ Therapeutic area breakdown
✓ Full indication list (19 indications)
✓ Patent cliff analysis
✓ Clinical trials pipeline
Upgrade to Pro
Starting at $99/mo
Drugs by Company
Johnson & Johnson 4 drugs
AstraZeneca 1 drug
IMCLONE 1 drug
By Therapeutic Area
Oncology 13 drugs
Other 4 drugs
Drugs by Company PRO
Johnson & Johnson 4 drugs
AstraZeneca 1 drug
IMCLONE 1 drug
MSN 1 drug
Cipla 1 drug
Takeda 1 drug
Boehringer Ingelheim 1 drug
Eli Lilly 1 drug
PUMA BIOTECH 1 drug
Sanofi 1 drug
+ 4 more companies
By Therapeutic Area
Oncology 13 drugs
ERBITUX, ERLOTINIB HYDROCHLORIDE, GEFITINIB, ALUNBRIG +9 more
Other 4 drugs
TAGRISSO, RYBREVANT, PORTRAZZA, CAPRELSA
Indications Treated
Non-Small Cell Lung CancerPancreatic CancerSquamous Non-Small Cell Lung CancerBreast CancerFirst-line treatment of locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R substitution mutations (in combination with lazertinib)Locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R substitution mutations that has progressed on or after treatment with an EGFR tyrosine kinase inhibitor (in combination with carboplatin and pemetrexed)First-line treatment of locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations (in combination with carboplatin and pemetrexed)Locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations that has progressed on or after platinum-based chemotherapy (as a single agent)Head and Neck CancerSquamous Cell Carcinoma of the Head and NeckColorectal CancerBRAF V600E Mutation-Positive Metastatic Colorectal CancerMedullary Thyroid CancerAdjuvant therapy after tumor resection in adult patients with EGFR exon 19 deletions or exon 21 L858R mutation-positive non-small cell lung cancer (NSCLC)Locally advanced, unresectable (stage III) EGFR exon 19 deletions or exon 21 L858R mutation-positive NSCLC that has not progressed during or following platinum-based chemoradiation therapyFirst-line treatment of adult patients with metastatic EGFR exon 19 deletions or exon 21 L858R mutation-positive NSCLCFirst-line treatment of adult patients with locally advanced or metastatic EGFR exon 19 deletions or exon 21 L858R mutation-positive NSCLC, in combination with pemetrexed and platinum-based chemotherapyMetastatic EGFR T790M mutation-positive NSCLC in patients whose disease has progressed on or after EGFR tyrosine kinase inhibitor therapyMetastatic Colorectal Cancer
All Drugs Targeting EGFR
| Drug | Company | Approved | Indications | Therapeutic Area |
|---|---|---|---|---|
| TAGRISSO | AstraZeneca | 2015 | 5 | |
| RYBREVANT | Johnson & Johnson | 2021 | 4 | |
| ERBITUX | IMCLONE | 2004 | 4 | Oncology |
| ERLOTINIB HYDROCHLORIDE | MSN | 2014 | 2 | Oncology |
| GEFITINIB | Cipla | 2022 | 1 | Oncology |
| ALUNBRIG | Takeda | 2017 | 1 | Oncology |
| GILOTRIF | Boehringer Ingelheim | 2013 | 1 | Oncology |
| RYBREVANT FASPRO | Johnson & Johnson | 2025 | 1 | Oncology |
| PORTRAZZA | Eli Lilly | 2015 | 1 | |
| NERLYNX | PUMA BIOTECH | 2017 | 1 | Oncology |
| CAPRELSA | Sanofi | 2011 | 1 | |
| VIZIMPRO | Pfizer | 2018 | 1 | Oncology |
| RYBREVANT FASPROI | Johnson & Johnson | 2026 | 1 | Oncology |
| VECTIBIX | Amgen | 2006 | 1 | Oncology |
| LAZCLUZE | Johnson & Johnson | 2024 | 1 | Oncology |
| HYRNUO | Bayer | 2025 | 1 | Oncology |
| TYKERB | Novartis | 2007 | 1 | Oncology |